Evidence map›Paper›PMID 40220220›Full record

ArticleBreast cancer research and treatment2025

Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy.

Hideo Shigematsu, Momoko Takaya, Kanako Suzuki, Mutsumi Fujimoto, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Koji Arihiro, Morihito Okada

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hideo ShigematsuDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan. shigematu1330@yahoo.co.jp.ORCID http://orcid.org/0000-0001-9393-9655
Momoko TakayaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.
Kanako SuzukiDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.
Mutsumi FujimotoDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.
Haruka IkejiriDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.
Ai AmiokaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.
Emiko HiraokaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.
Shinsuke SasadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.
Koji ArihiroDepartment of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, 734 - 8551, Japan.
Morihito OkadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1 - 2- 3-Kasumi, Minami-Ku, Hiroshima City, Hiroshima, 734 - 8551, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAxillary staging is commonly performed in patients with clinically node-positive (cN+) breast cancer undergoing neoadjuvant chemotherapy (NACT), regardless of pathological complete response (pCR). Recent evidence has suggested that ypT0 correlates with ypN0 and favorable prognosis, potentially supporting the omission of axillary staging in such cases. This study aimed to evaluate ypT0 as a predictive factor for ypN status and its prognostic significance in cN+ breast cancer treated with NACT.

methodsThis retrospective study included 302 patients with cN+ breast cancer treated with NACT at Hiroshima University Hospital between 2006 and 2022. Patients were categorized into non-pCR, ypTis, or ypT0 based on ypT status. Associations between breast pCR, ypN status, recurrence-free survival (RFS), and overall survival (OS) were analyzed.

resultsAmong 302 patients (non-pCR, 74.2%; ypTis, 8.9%; ypT0, 16.9%), the ypN+ rates were 63.3%, 15.2%, and 3.9%, respectively. Logistic regression revealed significant associations among ypT0, ypTis, and ypN0. The five-year RFS and OS rates were 78.6% and 85.2% (non-pCR), 83.8% and 95.5% (ypTis), and 98.0% and 100.0% (ypT0), respectively. Cox regression identified ypT0, but not ypTis, as a significant prognostic factor for both RFS and OS.

conclusionypT0 status was associated with a low risk of ypN+ and favorable clinical outcomes in cN+ breast cancer, suggesting the potential feasibility of omitting axillary surgery in select patients.

Indexed as

Breast NeoplasmsLymph NodesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAxillaChemotherapy, AdjuvantFemaleHumansLymphatic MetastasisLymph Node ExcisionMiddle AgedNeoadjuvant TherapyNeoplasm StagingPrognosisRetrospective StudiesAxillary surgery omissionBreast cancerNeoadjuvant chemotherapyYpN0YpT0

Identifiers

PMID40220220
PMCPMC12086105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.